SNX-2112 5mg
SNX-2112 is a heat shock protein 90 (Hsp90) inhibitor with anticancer properties currently in clinical trials. SNX-2112 induced autophagy in a time- and dose-dependent manner via Akt/mTOR/p70S6K inhibition. SNX-2112 induces significant apoptosis and autophagy in human melanoma A-375 cells, and may be an effective targeted therapy agent
Trivial name | SNX-2112 5mg |
Catalog Number | A11189-5 |
Alternative Name(s) | 2-[(trans-4-Hydroxycyclohexyl)amino]-4-[4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo-3-(trifluoromethyl)-1H-indazol-1-yl]benzamide |
Molecular Formula | C23H27F3N4O3 |
CAS# | 908112-43-6 |
SMILES | CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C |
Size | 5mg |
Supplier Page | http://www.adooq.com/snx-2112.html |